Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Ranjbar
 
IRCT20200204046369N1
RCTmethylprednisolonedexamethasoneCOVID 19 hospitalizedsome concern
44/42 suggested -54%
Metcovid
 
NCT04343729
RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
209/207 inconclusive -7%
RECOVERY dexamethasone
 
NCT04381936
RCTdexamethasonestandard of careCOVID 19 hospitalizedsome concern
2104/4321 conclusif demonstrated-15% -7%
Tang X
 
NCT04273321
RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
43/43 suggested -2% 4%

COVID-19 severe or critically meta-analysis

Jamaati
 
IRCT20151227025726N1
RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
25/25 suggested 17%
Munch (COVID-STEROID)
 
NCT04348305
RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
16/14 no results
CAPE-COVID
 
NCT02517489
RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
76/73 inconclusive -50% -26%
CODEX (Tomazini)
 
NCT04327401
RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
151/148 inconclusive -3%
DEXA-COVID19
 
NCT04325061
RCTdexamethasonestandard of careCOVID-19 severe or criticallylow
7/12 inconclusive 90%
Steroids-SARI
 
NCT04244591
RCTmethylprednisolonestandard of careCOVID-19 severe or criticallysome concern
24/23 inconclusive -8%
10 studies excluded by filtering options (6 RCT / 4 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).